KAUST and King Faisal Specialist Hospital and Research Centre (KFSHRC) are collaborating to develop an RNA sequencing tool to improve the diagnosis rate of genetic diseases. The tool analyzes RNA data to find aberrant transcripts and mutations, building on KFSHRC's clinical data and KAUST's computational expertise. The team has already solved cases that DNA sequencing alone could not, including a case of a young child with brain damage caused by a recessive gene mutation. Why it matters: This collaboration can improve disease management and preventative services in the region, directly contributing to Saudi Arabia’s national research priority of health and wellness.
A KAUST Rapid Research Response Team (R3T) is collaborating with healthcare stakeholders to combat COVID-19. Xin Gao and his Structural and Functional Bioinformatics (SFB) Group are developing an AI-based diagnosis pipeline from CT scans of COVID-19 patients. The AI pipeline aims to address the high false negative rates associated with nucleic acid detection. Why it matters: This research could improve COVID-19 diagnostics and potentially inform understanding of viral pathogenesis.
MBZUAI is developing AI algorithms to intelligently process data from wearables and home sensors for remote patient monitoring. The algorithms aim to analyze multiple strands of health data to provide a more comprehensive view of a patient's health, distinguishing between genuine emergencies and benign situations. MBZUAI's provost, Professor Fakhri Karray, believes this approach could handle 20-25% of diagnoses virtually, reducing the burden on healthcare systems. Why it matters: This research could significantly improve healthcare efficiency and accessibility in the UAE and beyond by enabling more effective remote patient monitoring and reducing unnecessary hospital visits.
MBZUAI researchers led by Dr. Mohammad Yaqub are developing AI algorithms for real-time medical diagnoses, including tools for multiple sclerosis and congenital heart disease. The team developed ScanNav, an AI fetal anomaly assessment system licensed by GE Healthcare for Voluson SWIFT ultrasound machines. ScanNav assists doctors during anomaly scans after 20 weeks of gestation to check for conditions like heart issues and spina bifida. Why it matters: This research has the potential to significantly improve the speed and accuracy of medical diagnoses in the UAE and beyond, addressing critical gaps in healthcare.
MBZUAI's BioMedIA lab, led by Mohammad Yaqub, is developing AI solutions for healthcare challenges in cardiology, pulmonology, and oncology using computer vision. Yaqub's previous research analyzed fetal ultrasound images to correlate bone development with maternal vitamin D levels. The lab is now applying image analysis to improve the treatment of head and neck cancer using PET and CT scans. Why it matters: This research demonstrates the potential of AI and computer vision to improve diagnostic accuracy and accessibility of healthcare in the region and beyond.
KAUST's Rapid Research Response Team (R3T), including Professor Samir Hamdan, is working to understand and counteract the spread of COVID-19. The team assembled a complete homemade, one-step RT-PCR test, comparable to commercial kits, with a patent-free manufacturing recipe. KAUST R3T is also researching faster, more accurate point-of-care tests, including a CRISPR-based molecular test. Why it matters: This research provides accessible testing solutions and contributes to more effective and rapid detection methods for combating viral spread in the region and globally.
KAUST's Laboratory of Stem Cells and Diseases, led by Assistant Professor Antonio Adamo, uses induced pluripotent stem cells (iPSCs) to model diseases like diabetes. The lab employs a reprogramming technique to revert patient fibroblasts into iPSCs, enabling the study of disease progression in vitro. Adamo's research focuses on enzymes and disregulated transcriptional/epigenetic mechanisms to understand disease onset. Why it matters: This research contributes to regenerative medicine and offers insights into metabolic diseases relevant to the GCC region.
MBZUAI researchers developed MedAgentSim, a simulated hospital environment to evaluate AI diagnostic abilities. The simulation uses LLM-powered agents to mimic doctor-patient conversations, providing a dynamic assessment of diagnostic skills. The system includes doctor, patient, and evaluator agents that interact within the simulated hospital, making real-time decisions. Why it matters: This research offers a more realistic evaluation of AI in clinical settings, addressing limitations of current benchmarks and potentially improving AI's use in healthcare.